Core Viewpoint - Sunshine Nuohua Pharmaceutical Research Co., Ltd. has received a first-instance judgment regarding a contract dispute over R&D expenses with Hunan Hengsheng Pharmaceutical Co., Ltd., which requires Hengsheng to pay 254,000 yuan in overdue R&D fees and corresponding penalties, while rejecting other claims from Sunshine Nuohua [1][2]. Group 1 - The court ruled that Hengsheng must pay Sunshine Nuohua 254,000 yuan within fifteen days from the judgment's effective date, along with a penalty calculated at a 5% annual interest rate from November 23, 2022, until actual payment [1]. - Sunshine Nuohua has fully provisioned for bad debts related to the overdue amount, indicating that the lawsuit will not negatively impact the company's current or future profits [2]. - The case is still within the appeal period, allowing Hengsheng to appeal to the Hunan Provincial High People's Court within fifteen days of receiving the judgment, introducing uncertainty regarding the final execution of the ruling [2].

阳光诺和(688621.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润为1.91亿元至 2.29亿元，与上年同期相比，增加1,364.26万元至5,185.30万元，同比增长7.69%到29.23%。 ...

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of the parent company between 191 million and 229 million yuan for the year 2025, indicating a year-on-year increase of 13.64 million to 51.85 million yuan, representing a growth rate of 7.69% to 29.23% compared to the previous year [1] Financial Performance - The projected net profit for 2025 is estimated to be between 191 million and 229 million yuan [1] - The expected increase in net profit ranges from 13.64 million to 51.85 million yuan compared to the previous year [1] - The anticipated year-on-year growth rate is between 7.69% and 29.23% [1]

Core Viewpoint - The company, 阳光诺和, expects a net profit attributable to shareholders for the year 2025 to be between 191.05 million and 229.26 million yuan, representing a year-on-year growth of 7.69% to 29.23% [1] - The company anticipates a net profit excluding non-recurring gains and losses to be between 179.70 million and 215.64 million yuan, with a year-on-year growth of 8.84% to 30.61% [1] Group 1: Revenue and Profit Growth - The company has achieved steady growth in revenue and profit, driven by the deep layout of its innovative drug pipeline, realization of value from licensing collaborations, and synergistic support from its integrated service model [1] - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy has provided solid support for business growth, leading to a steady improvement in the company's profitability [2] Group 2: Innovative Drug Pipeline - The company focuses on the research and development of innovative drugs with global independent intellectual property rights, constructing a pipeline matrix that includes over 20 first-class new drugs targeting major diseases such as cancer and pain [1] - Core pipelines like STC007 and STC008 have successfully entered critical clinical stages, generating stable income through R&D services and laying the foundation for long-term value release [1] Group 3: Licensing Collaborations - Licensing collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines such as STC007 and STC008, contributing to a high-margin revenue source [2] - The continuous optimization of the business structure is facilitated by these licensing agreements, enhancing the overall profitability of the company [2]

Core Insights - The company expects a net profit attributable to shareholders for the year 2025 to be between 191.05 million and 229.26 million yuan, representing a year-on-year growth of 7.69% to 29.23% [1] - The projected net profit after deducting non-recurring gains and losses is estimated to be between 179.70 million and 215.64 million yuan, with a year-on-year increase of 8.84% to 30.61% [1] Group 1 - The company's revenue and profit are showing steady growth, driven by the deep layout of its innovative drug pipeline, realization of value from licensing collaborations, and synergistic support from its integrated service model [1] - The innovative drug pipeline focuses on research and development of drugs with global intellectual property rights, covering cutting-edge areas such as peptides, small nucleic acids, cell and gene therapy, including over 20 first-class new drugs targeting major diseases like cancer and pain [1] - The company efficiently promotes R&D projects through a "preclinical + clinical" integrated service model, supported by a comprehensive quality management system and a clinical cooperation network with over 300 hospitals [1] Group 2 - Licensing collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines such as STC007 and STC008, contributing to a high-margin revenue source [2] - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy provides solid support for business growth, steadily enhancing the company's profitability [2]

证券代码：688621 证券简称：阳光诺和 公告编号：2026-005 北京阳光诺和药物研究股份有限公司 关于公司诉讼结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一审判决支付金额：湖南恒生制药股份有限公司（以下简称"恒生制药"） 向北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和"或"公司"）支付拖 欠研发费用合计 25.4 万元及相应逾期支付违约金。 是否会对上市公司损益产生负面影响：公司根据审慎性原则按照会计准 则已对恒生制药应收账款和合同资产全额计提了坏账准备，因此该诉讼事项对公 司当期及期后利润不会构成负面影响。截至本公告日，本案尚处于上诉期内，最 终执行情况尚存在不确定性，对公司造成的具体影响需以生效判决的实际执行情 况为准。 一、本次重大诉讼的基本情况 2025 年 8 月 2 日，阳光诺和在上海证券交易所网站（www.sse.com.cn）披露 了《北京阳光诺和药物研究股份有限公司关于公司诉讼事项进展暨提起新诉讼的 公告》（公告编号：2025-061），公司就恒生制药拖欠公 ...

Core Viewpoint - Sunshine Nuohuo (688621) expects a net profit attributable to shareholders of the parent company for the fiscal year 2025 to be between 191 million and 229 million yuan, representing a year-on-year growth of 7.69% to 29.23% [1] Group 1: Financial Performance - The company anticipates a net profit range of 191 million to 229 million yuan for 2025, indicating a positive growth trajectory [1] - The expected growth rate of net profit is between 7.69% and 29.23%, showcasing strong financial performance [1] Group 2: Revenue Sources - The company has generated significant revenue through intellectual property licensing transactions, contributing to high-margin income [1] - The authorized cooperation of pipelines such as STC007 and STC008 has provided considerable revenue, enhancing the company's financial stability [1] Group 3: Strategic Initiatives - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy has provided a solid foundation for business growth [1] - This strategic approach is driving steady improvements in the company's profitability [1]

证券代码：688621 证券简称：阳光诺和 公告编号：2026-004 北京阳光诺和药物研究股份有限公司 自愿披露 2025 年年度业绩预告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 经北京阳光诺和药物研究股份有限公司（以下简称"公司"）财务部门初步 测算： （1）预计 2025 年年度营业收入为 119,245.48 万元至 137,132.31 万元，与上 年同期相比，增加 11,398.10 万元至 29,284.93 万元，同比增长 10.57%到 27.15%。 （2）预计 2025 年利润总额为 19,578.57 万元至 23,494.28 万元，与上年同期 相比，增加 1,979.84 万元至 5,895.55 万元，同比增长 11.25%到 33.50%。 （3）预计 2025 年年度实现归属于母公司所有者的净利润为 19,105.21 万元 至 22,926.25 ...

Core Viewpoint - The company expects significant growth in revenue and profit for the year 2025 compared to the previous year, indicating a positive outlook for its financial performance [1] Financial Projections - The company anticipates annual operating revenue for 2025 to be between 1,192.45 million and 1,371.32 million yuan, representing an increase of 113.98 million to 292.85 million yuan, with a year-on-year growth rate of 10.57% to 27.15% [1] - The projected total profit for 2025 is expected to be between 195.79 million and 234.94 million yuan, an increase of 19.80 million to 58.96 million yuan, with a year-on-year growth rate of 11.25% to 33.50% [1] - The net profit attributable to the parent company's owners is forecasted to be between 191.05 million and 229.26 million yuan, an increase of 13.64 million to 51.85 million yuan, with a year-on-year growth rate of 7.69% to 29.23% [1]

（文章来源：证券日报） 证券日报网讯 1月16日，阳光诺和在互动平台回答投资者提问时表示，STC008注射液的核心适应症为 肿瘤恶液质，该适应症覆盖多种癌症类型引发的恶液质状态，并非仅局限于非小细胞肺癌。公司此前披 露的 STC008 国内BD协议中提及"非小细胞肺癌的恶液质"，系基于合作阶段的临床研发聚焦方向，目 前该产品正针对肿瘤恶液质开展 I 期临床试验，初步探索其在恶液质患者中的安全性与初步有效性，未 限定特定癌种。关于其他癌症类型恶液质的拓展，公司将在现有临床研究数据的基础上，结合临床需 求、研究进展及监管要求，审慎评估向多癌种恶液质拓展的可行性。 ...